Evidence map›Paper›PMID 37288665›Full record

ArticleJCI insight2023

A versatile laser-induced porcine model of outer retinal and choroidal degeneration for preclinical testing.

Francesca Barone, Juan Amaral, Irina Bunea, Mitra Farnoodian, Rohan Gupta, Rishabh Gupta, Dara Baker, M Joseph Phillips, Richard J Blanch, Arvydas Maminishkis and 2 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Transcriptomic Analysis of Organotypic Porcine Retina Cultures.International journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Animal models for the evaluation of retinal stem cell therapies.Progress in retinal and eye research · 2025
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Francesca BaroneNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
Juan AmaralNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
Irina BuneaNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
Mitra FarnoodianNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
Rohan GuptaNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
Rishabh GuptaNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
Dara BakerNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
M Joseph PhillipsMcPherson Eye Research Institute and Waisman Center, and.
Richard J BlanchAcademic Department of Military Surgery and Trauma, Royal Centre for Defense Medicine, Birmingham, United Kingdom.
Arvydas MaminishkisNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
David M GammMcPherson Eye Research Institute and Waisman Center, and.
Kapil BhartiNational Eye Institute (NEI), NIH, Bethesda, Maryland, USA.
National Eye Institute · USMcPherson College · USUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

Translational Research CoreZICEY000573 · NEI · NATIONAL EYE INSTITUTE · PI MAMINISHKIS, ARVYDAS · 2021 to 2025
$7.5M
6 · The paper itself

Abstract

Over 30 million people worldwide suffer from untreatable vision loss and blindness associated with childhood-onset and age-related eye diseases caused by photoreceptor (PR), retinal pigment epithelium (RPE), and choriocapillaris (CC) degeneration. Recent work suggests that RPE-based cell therapy may slow down vision loss in late stages of age-related macular degeneration (AMD), a polygenic disease induced by RPE atrophy. However, accelerated development of effective cell therapies is hampered by the lack of large-animal models that allow testing safety and efficacy of clinical doses covering the human macula (20 mm2). We developed a versatile pig model to mimic different types and stages of retinal degeneration. Using an adjustable power micropulse laser, we generated varying degrees of RPE, PR, and CC damage and confirmed the damage by longitudinal analysis of clinically relevant outcomes, including analyses by adaptive optics and optical coherence tomography/angiography, along with automated image analysis. By imparting a tunable yet targeted damage to the porcine CC and visual streak - with a structure similar to the human macula - this model is optimal for testing cell and gene therapies for outer retinal diseases including AMD, retinitis pigmentosa, Stargardt, and choroideremia. The amenability of this model to clinically relevant imaging outcomes will facilitate faster translation to patients.

Indexed as

Macular DegenerationRetinal DegenerationAnimalsChildChoroid DiseasesHumansRetinaRetinal Pigment EpitheliumSwineGene therapyOphthalmologyRetinopathyStem cellsStem cell transplantation

Identifiers

PMID37288665
PMCPMC10393234
OpenAlexW4379740175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.